New vaccine trial aims to train immune system against leukemia after transplant

This early-phase study tests a custom-made cancer vaccine (DC/AML fusion vaccine) for people with acute myeloid leukemia (AML) who have recently had a stem cell transplant. The vaccine is designed to teach the body's immune cells to recognize and attack remaining leukemia cells. Some participants also receive a low-dose chemotherapy drug (decitabine) to boost the vaccine's effect. The goal is to see if the vaccine is safe and can increase leukemia-fighting immune cells.